Last reviewed · How we verify

NCT05863221: HeronBariatric

ZYNRELEF® for Postoperative Analgesia After Laparoscopic Sleeve Gastrectomy

Status unknown Phase 4 Last updated 18 May 2023
What this trial tests

Phase 4 trial testing ZYNRELEF 200Mg-6Mg Extended-Release Solution in Post Operative Pain, Acute in 120 participants. Status unknown.

Timeline
9 May 2023
Primary endpoint
9 October 2024
9 October 2024

Quick facts

Lead sponsorDr. Yannis Raftopoulos
PhasePhase 4
StatusStatus unknown
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingnone
Primary purposetreatment
Enrollment120
Start date9 May 2023
Primary completion9 October 2024
Estimated completion9 October 2024
Sites1 location across United States

Drugs / interventions tested

Conditions studied

Sponsor

Dr. Yannis Raftopoulos

Who can join

18 and older, any sex, with Post Operative Pain, Acute or Bariatric Surgery Candidate. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Approximately 120 subjects will be randomized into 1 of the following 2 treatment groups in a 1:1 ratio: Group 1: ZYNRELEF® up to 200 mg/ 6mg ( 7ml vial) via instillation at all incision sites in addition to 30 ml of 0.5% Ropivacaine + 10mg dexamethasone. Postoperatively, intermittent IV acetaminophen will be administered as per need till discharge. Group 2: 30 ml of 0.5% Ropivacaine and 10mg dexamethasone into all surgical sites and intermittent IV acetaminophen as per need till discharge. Primary Objective: To compare the efficacy and duration of analgesia achieved following the instillation of ZYNRELEF® all incision sites in addition to Ropivacaine with dexamethasone + postoperative IV acetaminophen, to the standard treatment of Ropivacaine with dexamethasone + postoperative IV acetaminophen in subjects undergoing laparoscopic sleeve gastrectomy. Secondary Objectives: 1. To evaluate additional efficacy parameters, including opioid load, in this study population. 2. To determine the impact of ZYNRELEF® on the cost of pain management. 3. To assess the time taken to resume exercise after discharge. 4. To assess the adverse events reported following the use of ZYNRELEF®.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Post Operative Pain, Acute

Currently open trials in the same condition.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05863221.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing